Carboplatin Pharmachemie

Initial treatment of advanced ovarian carcinoma in established combination w/ other approved chemotherapeutic agents. Secondary/palliative treatment of patients w/ ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated w/ cisplatin.

Administer by IV infusion ≥15 min. Initial treatment of advanced ovarian carcinoma 300 mg/m² on day 1 every 4 wk for 6 cycles in combination therapy. Secondary treatment of recurrent ovarian carcinoma 360 mg/m² on day 1 every 4 wk as monotherapy. Patient w/ CrCl 41-59 mL/min 250 mg/m² on day 1, 16-40 mL/min 200 mg/m² on day 1.

History of severe allergic reactions to cisplatin or other platinum-containing compd. Severe bone marrow suppression or significant bleeding. Severe pre-existing renal impairment (CrCl ≤20 mL/min). Metastatic small cell carcinoma of the lung.

Reports of allergic reactions, including anaphylactic-like reactions. Risk of bone marrow suppression (leukopenia, neutropenia & thrombocytopenia). Frequently monitor peripheral blood counts (including platelets, WBCs, neutrophils, & Hb) during treatment &, when appropriate, until recovery is achieved. WBC counts <2,000 cells/mm³ or platelets <50,000 cells/mm³ may necessitate postponement of therapy until bone marrow recovery is evident. Myelosuppression, especially thrombocytopenia, may be more severe & prolonged in patients who have abnormal renal function or who are receiving concomitant therapy w/ nephrotoxic drugs. Assess renal function parameters prior to, during, & after therapy. Risk of decreases in CrCl <60 mL/min &, less frequently, rises in serum creatinine & BUN in patients who have previously experienced nephrotoxicity w/ cisplatin therapy. Anemia has been observed during treatment. Needles or IV sets containing Al parts that may come in contact w/ the drug must not be used for prep or administration. Gonadal suppression may occur in patients receiving antineoplastic therapy, especially alkylating agents. Potential hazard to the fetus. Women of childbearing potential should avoid becoming pregnant. Breastfeeding is not advised during therapy. Incidence of peripheral neurotoxicity is increased & myelotoxicity may be more severe in patients >65 yr.

Myelosuppression; nausea, vomiting, GI pain, diarrhea, constipation; renal toxicity, renal impairment; paresthesias, decreased deep tendon reflexes; tinnitus; LFT abnormalities, hypersensitivity reactions, pain, asthenia, alopecia, CV, resp, genitourinary & mucosal side effects.

Additive myelosuppressive effects w/ other myelosuppressive therapies. Increased incidence of carboplatin-induced neurotoxicity or ototoxicity in patients previously treated w/ cisplatin. Worsened pre-existing cisplatin-induced neurotoxicity or ototoxicity. Increased or exacerbated nephrotoxic potential w/ nephrotoxic compd. Decreased Ab response to vaccines. Concurrent use w/ live virus vaccine may potentiate the replication of vaccine virus & may increase adverse effects of vaccine virus.

Cytotoxic Chemotherapy

L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

P₁S₁S₃